Gen­fit throws in the tow­el on NASH, ex­it­ing a tu­mul­tuous field full of bright mar­ket prospects and lethal R&D set­backs

Gen­fit has had enough of NASH.

The French biotech $GN­FT says it’s looked at its failed Phase III from every an­gle, and sees no need to keep push­ing on elafi­bra­nor for NASH res­o­lu­tion with­out wors­en­ing fi­bro­sis. They’re now shut­ting down RE­SOLVE-IT, but they’ll keep work­ing on the drug, fo­cus­ing en­tire­ly on Pri­ma­ry Bil­iary Cholan­gi­tis (PBC) while con­tin­u­ing with its NASH di­ag­nos­tic tool NIS4.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER